Comparison of fludarabine plus mitoxantrone combination therapy with CHOP for malignant lymphoma
- VernacularTitle:氟达拉滨联合米托蒽醌与CHOP方案治疗恶性淋巴瘤的疗效比较
- Author:
Rui ZHANG
;
Jinxiang YU
;
Yan LI
- Publication Type:Journal Article
- Keywords:
Lymphoma,malignant;
Fludarabine;
CHOP regimen;
Efficacy;
Side effect
- From:
Chinese Journal of Practical Internal Medicine
2000;0(11):-
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the efficacy and safety of fludarabine plus mitoxantrone combination chemotherapy for malignant lymphoma compared with CHOP regimen.Methods Sixty-six patients with malignant lymphoma were divided into fludarabine group and CHOP group.The efficacy and toxicities of these two regimens were analyzed and compared between the two groups.Results The overall response(OR)was 81.5% in fludarabine group,while was 48.7% in CHOP;for the patients in late-stage,with B cell lymphoma,with T cell lymphoma and with high serum LDH level,the OR in fludarabine group was higher than in CHOP group obstructively,being 62.5% and 35.7%.Conclusion Fludarabine combination chemotherapy,as a first line regimen in treating first-treated lymphoma,recrudescent lymphoma,intractable lymphoma and lymphoma in late stage,possesses higher efficacy,safety and tolerance than CHOP regimen.
